ArticleJCO precision oncology2022

Clinical Response to Seribantumab, an Anti-Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an

Subotheni Thavaneswaran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.